Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides

US9539269B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9539269-B2
Application numberUS-201113334933-A
CountryUS
Kind codeB2
Filing dateDec 22, 2011
Priority dateDec 31, 2010
Publication dateJan 10, 2017
Grant dateJan 10, 2017

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Disclosed are methods of reducing the incidence of necrotizing enterocolitis in an infant, toddler, or child using nutritional compositions including human milk oligosaccharides. The nutritional compositions including the human milk oligosaccharides are effective in reducing inflammation and the incidence of inflammatory diseases.

First claim

Opening claim text (preview).

What is claimed is: 1. A method of reducing the incidence of necrotizing enterocolitis in an infant, toddler, or child, the method comprising administering to an infant, toddler, or child in need thereof, a nutritional composition comprising human milk oligosaccharides selected from the group consisting of 2′-fucosyllactose, lacto-N-neotetraose, and combinations thereof in a total amount of from about 0.001 mg/mL to about 20 mg/mL. 2. The method of claim 1 , wherein the composition comprises from 0.001 mg/mL to less than 2 mg/mL 2′-fucosyllactose. 3. The method of claim 1 , wherein the composition comprises from 0.001 mg/mL to less than 0.2 mg/mL lacto-N-neotetraose. 4. The method of claim 1 , wherein the composition further comprises at least one of a prebiotic, a probiotic, a long chain polyunsaturated fatty acid, an antioxidant, a milk protein of human origin, a milk protein of bovine origin, and a milk protein of combined bovine and human origin. 5. A method of reducing the incidence of necrotizing enterocolitis in an infant, toddler, or child, the method comprising administering to an infant, toddler, or child in need thereof a nutritional composition comprising 6′-sialyllactose, 2′-fucosyllactose, and lacto-N-neotetraose wherein the 6′-sialyllactose, 2′-fucosyllactose, and lacto-N-neotetraose are present in a total amount of from about 0.001 mg/mL to about 20 mg/mL. 6. The method of claim 5 , wherein the nutritional composition comprises from 0.001 mg/mL to less than 0.25 mg/mL 6′-sialyllactose. 7. The method of claim 5 , wherein the nutritional composition comprises from 0.001 mg/mL to less than 2 mg/mL 2′-fucosyllactose. 8. The method of claim 5 , wherein the nutritional composition comprises from 0.001 mg/mL to less than 0.2 mg/mL lacto-N-neotetraose. 9. The method of claim 5 , wherein the synthetic nutritional composition further comprises at least one of a prebiotic, a probiotic, a long chain polyunsaturated fatty acid, an antioxidant, and a milk protein of human origin, a milk protein of bovine origin, and a milk protein of combined bovine and human origin. 10. A synthetic formula for improving the feeding tolerance of an infant, toddler, or child, the synthetic formula comprising from about 0.001 mg/mL to about 20 mg/mL of an oligosaccharide blend and an emulsifying agent, wherein the oligosaccharide blend comprises a first oligosaccharide selected from the group consisting of a fructooligosaccharide, a galactooligosaccharide, lacto-N-neotetraose, 2′-fucosyllactose, and combinations thereof; a second oligosaccharide selected from the group consisting of 3′-sialyllactose, 6′-sialyllactose, and combinations thereof; and a third oligosaccharide selected from the group consisting of inulin, a gum, polydextrose, and combinations thereof. 11. The synthetic formula of claim 10 , wherein the oligosaccharide blend comprises from about 0.001 mg/mL to about 20 mg/mL of the first oligosaccharide, from about 0.001 mg/mL to about 20 mg/mL of the second oligosaccharide, and from about 0.05 mg/mL to about 20 mg/mL of the third oligosaccharide. 12. The synthetic formula of claim 10 , wherein the first oligosaccharide comprises lacto-N-neotetraose in a concentration of from 0.01 mg/mL to less than 0.2 mg/mL. 13. The synthetic formula of claim 10 , wherein the first oligosaccharide comprises lacto-N-neotetraose in a concentration of from greater than 0.32 mg/mL to 10 mg/mL. 14. The synthetic formula of claim 10 , wherein the first oligosaccharide comprises 2′-fucosyllactose in a concentration of from 0.001 mg/mL to less than 2.0 mg/mL. 15. The synthetic formula of claim 10 , wherein the first oligosaccharide comprises 2′-fucosyllactose in a concentration of from greater than 2.5 mg/mL to 10 mg/mL. 16. The synthetic formula of claim 10 , wherein the second oligosaccharide comprises 6′-sialyllactose in a concentration of from 0.001 mg/mL to less than 0.25 mg/mL. 17. The synthetic formula of claim 10 , wherein the second oligosaccharide comprises 6′-sialyllactose in a concentration of from greater than 0.4 mg/mL to 10 mg/mL. 18. A method of improving the feeding tolerance of an infant, toddler, or child in need thereof, the method comprising administering to the infant, toddler, or child a nutritional composition comprising from about 0.001 mg/mL to about 20 mg/mL of an oligosaccharide blend, wherein the oligosaccharide blend comprises a first oligosaccharide selected from the group consisting of a fructooligosaccharide, a galactooligosaccharide, lacto-N-neotetraose, 2′-fucosyllactose, and combinations thereof; a second oligosaccharide selected from the group consisting of 3′-sialyllactose, 6′-sialyllactose, and combinations thereof; and a third oligosaccharide selected from the group consisting of inulin, a gum, polydextrose, and combinations thereof.

Assignees

Inventors

Classifications

  • Free radical scavengers or antioxidants · CPC title

  • Nutrients, e.g. vitamins, minerals · CPC title

  • Drugs for disorders of the alimentary tract or the digestive system · CPC title

  • Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula · CPC title

  • from milk · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9539269B2 cover?
Disclosed are methods of reducing the incidence of necrotizing enterocolitis in an infant, toddler, or child using nutritional compositions including human milk oligosaccharides. The nutritional compositions including the human milk oligosaccharides are effective in reducing inflammation and the incidence of inflammatory diseases.
Who is the assignee on this patent?
Chow Jomay, Davis Steven R, Buck Rachael, and 3 more
What technology area does this patent fall under?
Primary CPC classification A61K31/702. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Jan 10 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).